Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada.

ABSTRACT:

Introduction

The propensity for influenza viruses to mutate and recombine makes them both a familiar threat and a prototype emerging infectious disease. Emerging evidence suggests that the use of MF59-adjuvanted vaccines in older adults and young children enhances protection against influenza infection and reduces adverse influenza-attributable outcomes compared to unadjuvanted vaccines. The health and economic impact of such vaccines in the Canadian population are uncertain.

Methods

We constructed an age-structured compartmental model simulating the transmission of influenza in the Canadian population over a ten-year period. We compared projected health outcomes (quality-adjusted life years (QALY) lost), costs, and incremental cost-effectiveness ratios (ICERs) for three str

SUBMITTER: Fisman DN 

PROVIDER: S-EPMC3215749 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature